| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate |
2007-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f940adb4d09f621ab93ccd647b0236ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_210dabb26350aebe7f3fdd417006995b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23b38d2ad86e198b26d7bbbb371d0d52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_febd8e4e77fd22692b2a5c2dad9558a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18abfee5da7467c479da409436841921
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb8a4fd55090cf821c94b3429964bd12 |
| publicationDate |
2011-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8025881-B2 |
| titleOfInvention |
BMP antibodies and methods of treating kidney disease using the same |
| abstract |
When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9359645-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010135988-A1 |
| priorityDate |
2006-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |